Mirador Therapeutics
Allison Luo, MD is currently the Chief Medical Officer at Mirador Therapeutics and serves as a Member of the Board of Directors at Triveni Bio. With a background as the Chief Medical Officer at various pharmaceutical and biotech companies such as Prometheus Biosciences, Inc., OPPILAN PHARMA LIMITED (now Ventyx Biosciences), and Escalier Biosciences B.V., Allison brings a wealth of experience to their current roles. Prior to their current positions, Allison held leadership roles at Progenity, Inc., Ophthotech Corporation, Bristol Myers Squibb, and Abbott. Allison obtained their Doctor of Medicine degree from Northwestern University - The Feinberg School of Medicine and a Bachelor of Science in Biochemistry from Northwestern University.
This person is not in any offices
Mirador Therapeutics
Mirador is a next-generation precision medicine company focused on immunology and inflammation. The company’s Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases. Launched in 2024, Mirador has raised over $400 million from leading life sciences investors and is based in San Diego, CA.